Glycoprotein News and Research

RSS

Genomic expansion and diversification in a African sleeping sickness parasite allow it to evade host detection

A team of scientists headed by Dr. Sara Melville at the University of Cambridge has shown that the parasite known to cause African sleeping sickness has evolved an unusual chromosomal structure as a result of environmental adaptation.

3 Aug 2006

New polymer-lipid hybrid nanoparticle

A novel combination of lipids, a negatively charged polymer, and the anticancer drug doxorubicin has yielded a new nanoparticle that can kill breast cancer cells that are normally resistant to this drug.

3 Jul 2006

Study calls for more consistent use of anti-clotting medications in women

High-risk women with acute coronary syndrome benefit as much as men from a trip to the cardiac cath lab shortly after being hospitalized, according to a study reported recently at the Society for Cardiovascular Angiography and Interventions (SCAI) 29th Annual Scientific Sessions in Chicago.

17 May 2006

Antifibrotic effect of hepatocyte growth factor is impaired in lung fibroblasts isolated from African-Americans

Of the more than 40,000 persons who die each year in the U.S. from pulmonary fibrosis, the mortality rate among African-Americans is twice as high Caucasians.

11 Apr 2006

Emergence of a human-adapted H5 virus is a clear threat to public health worldwide

The H5N1 avian influenza virus, commonly known as "bird flu," is a highly contagious and deadly disease in poultry. So far, its spread to humans has been limited, with 177 documented severe infections, and nearly 100 deaths in Indonesia, Vietnam, Thailand, Cambodia, China, Iraq, and Turkey as of March 14, 2006, according to the World Health Organization.

21 Mar 2006

Researchers evaluate efficacy, safety of anti-clotting drugs

Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI.

15 Mar 2006

The safety and effectiveness of fondaparinux for heart attacks

The results of a large international cardiovascular trial will shed light on whether the addition of a new drug that prevents blood clotting, or thrombosis, can improve the treatment of the most serious form of heart attacks.

15 Mar 2006

Ebola DNA vaccine shows promise

Vical Incorporated has announced that an Ebola vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated, and produced both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full 3 doses of vaccine.

21 Feb 2006

Surprise discovery helps tackle rabies

In an unexpected discovery, scientists at Jefferson Medical College have found that a tiny change in a rabies virus protein can turn a "safe" virus extremely deadly. The finding has enabled the researchers to refine a vaccine they previously created against rabies in wildlife, making it safer and more effective.

5 Jan 2006

Too high blood-thinner doses harmful to patients

According to a new analysis by cardiologists at the Duke Clinical Research Institute, in the prescribing of common but powerful anti-clotting drugs, 42 percent of patients rushed to emergency rooms with symptoms of a heart attack received doses intended to stop clotting in coronary arteries above the recommended range.

29 Dec 2005

Misdosing anti-clotting drugs leads to heart attack symptoms

Because of inaccuracies in prescribing, 42 percent of patients rushed to emergency rooms with symptoms of a heart attack received doses of powerful drugs intended stop clotting in coronary arteries outside of the recommended range, a new analysis by Duke Clinical Research Institute (DCRI) cardiologists has found.

28 Dec 2005

Functional amyloid formation within mammalian tissue

What do neurodegenerative diseases and suntans have in common? Scientists at the Scripps Research Institute have found an intriguing molecular connection.

7 Dec 2005

Physicians slow to prescribe newer heart drugs

An analysis of the treatment received by more than 100,000 heart patients has shown that physicians' prescription practices for drugs proven effective for treating heart disease has shown steady improvement over the past three years, cardiologists at the Duke Clinical Research Institute (DCRI) have concluded.

7 Dec 2005

Unexpected link between muscular dystrophy and muscle wasting associated with cancer

A new study provides important insight into the mechanisms of a muscle wasting disorder that interferes with treatment for cancer and has a negative impact on patient survival.

5 Dec 2005

American physicians may be too liberal in their use of blood transfusions

In an analysis of some 24,000 patient records, the researchers found that Americans rushed to the hospital with heart attack symptoms have significantly higher rates of bleeding and transfusions after treatment than similar patients throughout the world.

21 Nov 2005

Better understanding of cancer cachexia

New research shows that a wasting condition responsible for nearly a third of all cancer deaths involves the loss of an essential muscle protein that is also lost in people with muscular dystrophy.

15 Nov 2005

Mixed carbon nanotubes and standard urban particulates suggests a risk of thrombosis from airborne pollution

Carbon nanoparticles - both those unleashed in the air by engine exhaust and the engineered structures thought to have great potential in medical applications - promote blood-clotting, scientists report in an upcoming edition of the British Journal of Pharmacology.

23 Oct 2005

Molecule P-glycoprotein (Pgp), may help reduce risk of Alzheimer's

A molecule that has long been an obstacle to cancer chemotherapy and drug treatments for brain disorders may soon become an ally in the fight against Alzheimer's disease, according to researchers at Washington University School of Medicine in St. Louis and the University of Rochester.

20 Oct 2005

Alzheimer disease and the blood brain barrier

Increased production of the amyloid-beta (Abeta) peptide can lead to Abeta aggregation and buildup in the brain and rare familial forms of early onset Alzheimer disease (AD).

20 Oct 2005

Nabi Biopharmaceuticals granted Staphylococcus Antigen and Vaccine patent

Nabi Biopharmaceuticals has announced that it has been granted U.S. Patent No. 6,936,258 entitled "Staphylococcus Antigen and Vaccine" by the U.S. Patent and Trademark Office for the composition of a strategically important glycoprotein-based antigen (GP-1) associated with three Staphylococcal strains: S. epidermidis, S. haemolyticus and S. hominis.

11 Oct 2005